Genscript Biotech initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Genscript Biotech with a Buy rating and HK$29.34 price target, implying 31% upside from current levels. The analyst says cell and gene therapies are seeing expanded adoption which could drive up the market potential. The company demonstrates potential solutions that could be critical in driving more explosive growth of cell and gene therapies particularly autologous cell therapies, the analyst tells investors in a research note.